UBS Group AG
- SEC CIK
- 0001610520
- Latest filing
- Aug 13, 2026
NRSNW holding history
NeuroSense Therapeutics Ltd. in every 13F filed by UBS Group AG, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
NRSNW overviewAll 13F holders of NRSNWFull Q2 2026 holdings
- Shares (Q2 2026)
- 1,163
- Value
- $73
- % of portfolio
- <0.1%
- Quarters held
- 13
- Since Q4 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 1,163 | $73 | <0.1% | 00.0% | Unchanged | Holders |
| Q1 2026 | 1,163 | $64 | <0.1% | 00.0% | Unchanged | Holders |
| Q4 2025 | 1,163 | $291 | <0.1% | −117−9.1% | Reduced | Holders |
| Q3 2025 | 1,280 | $397 | <0.1% | −190−12.9% | Reduced | Holders |
| Q2 2025 | 1,470 | $932 | <0.1% | −1,371−48.3% | Reduced | Holders |
| Q1 2025 | 2,841 | $582 | <0.1% | +2,747+2,922.3% | Added | Holders |
| Q4 2024 | 94 | $41 | <0.1% | −106−53.0% | Reduced | Holders |
| Q3 2024 | 200 | $28 | <0.1% | −405−66.9% | Reduced | Holders |
| Q2 2024 | 605 | $125 | <0.1% | +605 | New | Holders |
| Q4 2023 | 0 | $0 | 0.0% | −3,802−100.0% | Sold out | Holders |
| Q3 2023 | 3,802 | $422 | <0.1% | +3,802 | New | Holders |
| Q1 2023 | 0 | $0 | 0.0% | −798−100.0% | Sold out | Holders |
| Q4 2022 | 798 | $128 | <0.1% | −1,160−59.2% | Reduced | Holders |
| Q3 2022 | 1,958 | $0 | 0.0% | +1,958 | New | Holders |
| Q1 2022 | 0 | $0 | 0.0% | −4,491−100.0% | Sold out | Holders |
| Q4 2021 | 4,491 | $4.00K | <0.1% | +4,491 | New | Holders |